Product Review – Elotuzumab in Relapsed/Refractory Multiple Myeloma

As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Elotuzumab in relapsed and/or refractory Multiple Myeloma.

This review discusses current treatment recommendations, pharmacological properties, mechanism of action and major studies featuring Elotuzumab. It also provides commentary and recommendations from Dr Hasib Sidiqi, a consultant haematologist at Fiona Stanley Hospital in Perth and an adjunct Associate Professor through Curtin Medical School.

Please login below to download this issue (PDF)

Subscribe